beraprost (BioDeep_00000176604)

   

human metabolite blood metabolite


代谢物信息卡片


4-[4-hydroxy-3-(3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-7-oxatricyclo[6.4.0.0^{2,6}]dodeca-1(8),9,11-trien-9-yl]butanoic acid

化学式: C24H30O5 (398.209313)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC#CCC(C)C(O)C=CC1C(O)CC2OC3=C(C=CC=C3CCCC(O)=O)C12
InChI: InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)



数据库引用编号

4 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Xinyu Liang, Yuzhen Wang, Cheng Zhao, Yemin Cao. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis. PloS one. 2022; 17(11):e0275392. doi: 10.1371/journal.pone.0275392. [PMID: 36318524]
  • Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Kamran Hessami, Mojtaba Shabani-Borujeni, Mahnaz Hosseini-Bensenjan, Shahla Rezaei, Mohammad Jalali, Pedram Keshavarz, Fariba Ahmadizar. The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus: a systematic review and meta-analysis of clinical trials. International urology and nephrology. 2022 Jan; 54(1):111-120. doi: 10.1007/s11255-021-02887-7. [PMID: 34019221]
  • Ikumi Nakajo, Hiroshi Inoue, Masaki Inaba, Keishi Oikawa, Masataka Katashima, Taiji Sawamoto, Hajimu Kurumatani, Masanari Shiramoto. Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males. Clinical drug investigation. 2021 Jun; 41(6):549-555. doi: 10.1007/s40261-021-01031-8. [PMID: 33913081]
  • Daoyuan Sun, Wenlan Yang, Zhenwei Wang, Beilan Gao. Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension. Medical science monitor : international medical journal of experimental and clinical research. 2021 Feb; 27(?):e928413. doi: 10.12659/msm.928413. [PMID: 33531453]
  • Pingli Li, Rui Zhang, Guiyan Yuan, Keguang Chen, Huanjun Liu, Yanyan Wang, Abdul Sami Shaikh, Benjie Wang, Rong Li, Ruichen Guo. Pharmacokinetics and vasodilating effect study of beraprost sodium in healthy volunteers. Pakistan journal of pharmaceutical sciences. 2020 Jul; 33(4):1659-1664. doi: NULL. [PMID: 33583799]
  • Daigoro Hirohama, Wakako Kawarazaki, Mitsuhiro Nishimoto, Nobuhiro Ayuzawa, Takeshi Marumo, Shigeru Shibata, Toshiro Fujita. PGI2 Analog Attenuates Salt-Induced Renal Injury through the Inhibition of Inflammation and Rac1-MR Activation. International journal of molecular sciences. 2020 Jun; 21(12):. doi: 10.3390/ijms21124433. [PMID: 32580367]
  • Hidetomo Nakamoto, Xue-Qing Yu, Suhnggwon Kim, Hideki Origasa, Hongguang Zheng, Jianghua Chen, Kwon Wook Joo, Suchai Sritippayawan, Qinkai Chen, Hung-Chun Chen, Yoshiharu Tsubakihara, Hirofumi Tamai, Sang Heon Song, Indralingam Vaithilingam, Kang Wook Lee, Kuo-Hsiung Shu, Stanley Hok-King Lo, Masanao Isono, Hajimu Kurumatani, Kiyonobu Okada, Hiroyuki Kanoh, Takashi Kiriyama, Shunsuke Yamada, Toshiro Fujita. Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2020 Feb; 24(1):42-55. doi: 10.1111/1744-9987.12840. [PMID: 31119846]
  • Ling Xie, Ruonan Zhai, Teng Chen, Chongting Gao, Rui Xue, Niansong Wang, Jianbo Wang, Youhua Xu, Dingkun Gui. Panax Notoginseng Ameliorates Podocyte EMT by Targeting the Wnt/β-Catenin Signaling Pathway in STZ-Induced Diabetic Rats. Drug design, development and therapy. 2020; 14(?):527-538. doi: 10.2147/dddt.s235491. [PMID: 32103895]
  • Yun Mi Choi, Hyuk Sang Kwon, Kyung Mook Choi, Won Young Lee, Eun Gyoung Hong. Short-Term Effects of Beraprost Sodium on the Markers for Cardiovascular Risk Prediction in Type 2 Diabetic Patients with Microalbuminuria. Endocrinology and metabolism (Seoul, Korea). 2019 12; 34(4):398-405. doi: 10.3803/enm.2019.34.4.398. [PMID: 31884740]
  • Shulin Li, Yanping Wang, Lu Chen, Zhuojun Wang, Guodong Liu, Bangjie Zuo, Caixia Liu, Dong Sun. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels. Journal of molecular medicine (Berlin, Germany). 2019 06; 97(6):777-791. doi: 10.1007/s00109-019-01769-x. [PMID: 30923844]
  • Budi Prasaja, Yahdiana Harahap, Windy Lusthom, Anna Sofiana, Falah Safira, Monika Sandra, Girinanda Puspanegara. Study on bioequivalence of beraprost in healthy volunteers by liquid chromatography with tandem mass spectrometry. Biomedical chromatography : BMC. 2019 Feb; 33(2):e4403. doi: 10.1002/bmc.4403. [PMID: 30276833]
  • Ziming Wan, Ying Zhu, Ruikun Yang, Yongjian Zhang, Chen Yang, Lei Cao, Wenjing Yan, Qi Wang, Ning Li, Mingdong Zhao, Keke Gui, Min Xiong. Beraprost sodium versus clopidogrel for preventing vascular thromboembolic events of arteriovenous fistula in uraemic patients: a retrospective study with a mean 3-year follow-up. The Journal of international medical research. 2019 Jan; 47(1):252-264. doi: 10.1177/0300060518800517. [PMID: 30270798]
  • Yu Zhou, Ling Du, Bo Tu, Qiquan Lai, Xiaonan Du, Bo Xu, Fan Zhang, Mingdong Zhao, Ziming Wan, Jiajie Lai. Comparing the vascular thromboembolic events following arteriovenous fistula in Chinese population with end-stage renal diseases receiving Clopidogrel versus Beraprost sodium therapy: a retrospective cohort study. BMC nephrology. 2018 12; 19(1):376. doi: 10.1186/s12882-018-1166-0. [PMID: 30587157]
  • Xin-Fang Wang, Bei-Hao Zhang, Xiao-Qing Lu, Pei Wang. Beraprost Sodium, a Stable Analogue of PGI2, Inhibits the Renin-Angiotensin System in the Renal Tissues of Rats with Chronic Renal Failure. Kidney & blood pressure research. 2018; 43(4):1231-1244. doi: 10.1159/000492405. [PMID: 30078019]
  • M Takenaka, A Iio, R Sato, T Sakamoto, H Kurumatani. A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease. Journal of veterinary internal medicine. 2018 Jan; 32(1):236-248. doi: 10.1111/jvim.14839. [PMID: 29131397]
  • Jingfan Deng, Jiao Feng, Tong Liu, Xiya Lu, Wenwen Wang, Ning Liu, Yang Lv, Qing Liu, Chuanyong Guo, Yingqun Zhou. Beraprost sodium preconditioning prevents inflammation, apoptosis, and autophagy during hepatic ischemia-reperfusion injury in mice via the P38 and JNK pathways. Drug design, development and therapy. 2018; 12(?):4067-4082. doi: 10.2147/dddt.s182292. [PMID: 30568428]
  • Pengyuan Zhang, Lijuan Xu, Hongyu Guan, Liehua Liu, Juan Liu, Zhimin Huang, Xiaopei Cao, Zhihong Liao, Haipeng Xiao, Yanbing Li. Beraprost sodium, a prostacyclin analogue, reduces fructose-induced hepatocellular steatosis in mice and in vitro via the microRNA-200a and SIRT1 signaling pathway. Metabolism: clinical and experimental. 2017 08; 73(?):9-21. doi: 10.1016/j.metabol.2017.05.003. [PMID: 28732575]
  • Miyeon Kim, Ji Ung Kim, So Mi Kim, HyunWoo Kim. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis. International urology and nephrology. 2017 Jul; 49(7):1287-1295. doi: 10.1007/s11255-017-1586-y. [PMID: 28409403]
  • Jongseon Choe, Yongdae Yoon, Jini Kim, Yu-Jin Jung. Positive feedback effect of PGE2 on cyclooxygenase-2 expression is mediated by inhibition of Akt phosphorylation in human follicular dendritic cell-like cells. Molecular immunology. 2017 07; 87(?):60-66. doi: 10.1016/j.molimm.2017.04.004. [PMID: 28407559]
  • Masahiro Shimamura, Jun Miyakawa, Masaaki Doi, Kiyonobu Okada, Hajimu Kurumatani, Yoshitaka Mori, Keiyu Oshida, Ikumi Nakajo, Keishi Oikawa, Fumihiko Ushigome, Aiji Miyashita, Masanao Isono, Yohei Miyamoto. The Pharmacokinetics of Beraprost Sodium Following Single Oral Administration to Subjects With Impaired Kidney Function. Journal of clinical pharmacology. 2017 04; 57(4):524-535. doi: 10.1002/jcph.835. [PMID: 27681484]
  • Satoshi Akagi, Kazufumi Nakamura, Hiromi Matsubara, Megumi Kondo, Daiji Miura, Tetsuya Matoba, Kensuke Egashira, Hiroshi Ito. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension. Journal of cardiovascular pharmacology. 2016 Apr; 67(4):290-8. doi: 10.1097/fjc.0000000000000352. [PMID: 26745002]
  • Noelia Perez Diaz, Mire Zloh, Pryank Patel, Louise S Mackenzie. In silico modelling of prostacyclin and other lipid mediators to nuclear receptors reveal novel thyroid hormone receptor antagonist properties. Prostaglandins & other lipid mediators. 2016 Jan; 122(?):18-27. doi: 10.1016/j.prostaglandins.2015.12.002. [PMID: 26686607]
  • Akio Koyama, Toshiro Fujita, Fumitake Gejyo, Hideki Origasa, Masanao Isono, Hajimu Kurumatani, Kiyonobu Okada, Hiroyuki Kanoh, Takashi Kiriyama, Shunsuke Yamada. Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial. BMC nephrology. 2015 Oct; 16(?):165. doi: 10.1186/s12882-015-0130-5. [PMID: 26475266]
  • Jenny S McKean, Fiona Murray, George Gibson, Derryck A Shewan, Steven J Tucker, Graeme F Nixon. The cAMP-producing agonist beraprost inhibits human vascular smooth muscle cell migration via exchange protein directly activated by cAMP. Cardiovascular research. 2015 Sep; 107(4):546-55. doi: 10.1093/cvr/cvv176. [PMID: 26092100]
  • Hitoshi Kashiwagi, Koh-Ichi Yuhki, Fumiaki Kojima, Shima Kumei, Osamu Takahata, Yoshiki Sakai, Shuh Narumiya, Fumitaka Ushikubi. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. The Journal of pharmacology and experimental therapeutics. 2015 May; 353(2):269-78. doi: 10.1124/jpet.115.222612. [PMID: 25740898]
  • Sinan Vicil, Suat Erdoğan. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cells. Turkish journal of medical sciences. 2015; 45(2):284-90. doi: 10.3906/sag-1401-108. [PMID: 26084116]
  • Ayaka Shima, Masaaki Miyamoto, Yoshiaki Kubota, Gen Takagi, Wataru Shimizu. Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2015; 82(2):84-91. doi: 10.1272/jnms.82.84. [PMID: 25959199]
  • Hidetomo Nakamoto, Toshiro Fujita, Hideki Origasa, Masanao Isono, Hajimu Kurumatani, Kiyonobu Okada, Hiroyuki Kanoh, Takashi Kiriyama, Shunsuke Yamada. A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC nephrology. 2014 Sep; 15(?):153. doi: 10.1186/1471-2369-15-153. [PMID: 25233856]
  • Yasufumi Goto, Shinichi Yamaguchi, Mitsutaka Tamura, Hidenori Mochizuki, Hajimu Kurumatani, Kiyoshi Okano, Mitsuko Miyamoto. A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis. Prostaglandins & other lipid mediators. 2014 Aug; 112(?):16-26. doi: 10.1016/j.prostaglandins.2014.06.001. [PMID: 24992870]
  • J Guan, L Long, Y-Q Chen, Y Yin, L Li, C-X Zhang, L Deng, L-H Tian. Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy. Genetics and molecular research : GMR. 2014 Jun; 13(2):4154-8. doi: 10.4238/2014.june.9.1. [PMID: 25036159]
  • Takayasu Ohtake, Motoyoshi Sato, Ryoichi Nakazawa, Morihiro Kondoh, Takehiko Miyaji, Hidekazu Moriya, Sumi Hidaka, Shuzo Kobayashi. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2014 Feb; 18(1):1-8. doi: 10.1111/1744-9987.12051. [PMID: 24499078]
  • Chabha Benyahia, Kamel Boukais, Ingrid Gomez, Adam Silverstein, Lucie Clapp, Aurélie Fabre, Claire Danel, Guy Leséche, Dan Longrois, Xavier Norel. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. Prostaglandins & other lipid mediators. 2013 Dec; 107(?):48-55. doi: 10.1016/j.prostaglandins.2013.07.001. [PMID: 23850788]
  • Jini Kim, Seungkoo Lee, Young-Myeong Kim, Doo-Il Jeoung, Jongseon Choe. Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins. Molecular immunology. 2013 Oct; 55(3-4):418-23. doi: 10.1016/j.molimm.2013.03.019. [PMID: 23583086]
  • Yi Chen, Jian-Xin Wan, De-Wen Jiang, Bin-Bin Fu, Jiong Cui, Gui-Fen Li. [Clinical efficacy and safety of sequential treatment with alprostadil and beraprost sodium for chronic renal failure induced by chronic glomerulonephritis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2013 Oct; 33(10):1521-4. doi: NULL. [PMID: 24144760]
  • Takahisa Yano. [Cellular and molecular mechanisms in drug-induced nephrotoxicity and its prevention]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2013 Oct; 142(4):172-7. doi: 10.1254/fpj.142.172. [PMID: 24107521]
  • Ki Young Na, Dong Ki Kim, Sung Gyun Kim, Young-Ki Lee, Chun Soo Lim. Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy. Trials. 2013 Sep; 14(?):275. doi: 10.1186/1745-6215-14-275. [PMID: 24066672]
  • Shinichi Yamaguchi, Chifumi Inada, Mitsutaka Tamura, Nahoko Sato, Masateru Yamada, Shoichi Itaba, Seiji Okazaki, Hirotoshi Matsuura, Shigeo Fujii, Fuko Matsuda, Yasufumi Goto, Hidenori Mochizuki, Hajimu Kurumatani, Mitsuko Miyamoto. Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5/6 nephrectomized chronic kidney disease rats. European journal of pharmacology. 2013 Aug; 714(1-3):325-31. doi: 10.1016/j.ejphar.2013.07.032. [PMID: 23911885]
  • Eunjoo Lee, Jini Kim, Young-Myeong Kim, Kwon Soo Ha, Doo-Il Jeoung, Jeong-Im Sin, Jongseon Choe. Beraprost enhances production of antigen-specific IgG isotypes without modulating germinal center B cell generation and the affinity maturation. International immunopharmacology. 2013 Apr; 15(4):735-42. doi: 10.1016/j.intimp.2013.03.004. [PMID: 23499642]
  • Yukiko Nozawa, Ayako Sato, Hoglan Piao, Tetsuo Morioka, Ichiei Narita, Takashi Oite. The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I2 analog on the progression of sclerotic glomerulonephritis in rats. Clinical and experimental nephrology. 2012 Apr; 16(2):221-30. doi: 10.1007/s10157-011-0558-2. [PMID: 22147282]
  • Shunji Yoshida, Kunio Shirato, Ryutaro Shimamura, Norie Nakahara, Takayuki Iwase, Hiromu Nakajima. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. Current medical research and opinion. 2011 Sep; 27(9):1827-34. doi: 10.1185/03007995.2011.605440. [PMID: 21812736]
  • Jini Kim, Chan-Sik Park, Chan-Hum Park, Doo-Il Jeoung, Young-Myeong Kim, Jongseon Choe. Beraprost enhances the APC function of B cells by upregulating CD86 expression levels. Journal of immunology (Baltimore, Md. : 1950). 2011 Apr; 186(7):3866-73. doi: 10.4049/jimmunol.1002170. [PMID: 21339360]
  • Hidekazu Moriya, Kunihiro Ishioka, Kenjiro Honda, Machiko Oka, Kyoko Maesato, Ryota Ikee, Sumi Hidaka, Takayasu Ohtake, Shuzo Kobayashi. Beraprost sodium, an orally active prostaglandin I(2) analog, improves renal anemia in hemodialysis patients with peripheral arterial disease. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2010 Oct; 14(5):472-6. doi: 10.1111/j.1744-9987.2010.00814.x. [PMID: 21175545]
  • Maho Watanabe, Hitoshi Nakashima, Kenji Ito, Katsuhisa Miyake, Takao Saito. Improvement of dyslipidemia in OLETF rats by the prostaglandin I(2) analog beraprost sodium. Prostaglandins & other lipid mediators. 2010 Sep; 93(1-2):14-9. doi: 10.1016/j.prostaglandins.2010.04.003. [PMID: 20450981]
  • Nahoko Sato, Masayuki Kaneko, Mitsutaka Tamura, Hajimu Kurumatani. The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats. Diabetes. 2010 Apr; 59(4):1092-100. doi: 10.2337/db09-1432. [PMID: 20068136]
  • H Shigematsu, T Nishibe, Y Obitsu, K Matsuzaki, A Ishida, T Miyata, S Shindo, K Hida, T Ohta, M Ando, T Kawasaki, T Yasugi, T Matsumoto. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD). International angiology : a journal of the International Union of Angiology. 2010 Apr; 29(2 Suppl):2-13. doi: NULL. [PMID: 20357743]
  • Takeyoshi Kunieda, Norifumi Nakanishi, Hiromi Matsubara, Tohru Ohe, Yoshiaki Okano, Hirobumi Kondo, Masaharu Nishimura, Kunio Shirato, Nobuhiro Tanabe, Satoshi Homma, Shunji Yoshida, Shigeko Inokuma, Makoto Kodama, Takao Koike, Hitoshi Hishida. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. International heart journal. 2009 Jul; 50(4):513-29. doi: 10.1536/ihj.50.513. [PMID: 19609055]
  • Masahiko Takenaka, Noboru Machida, Nobutaka Ida, Nahoko Satoh, Hajimu Kurumatani, Yoshihisa Yamane. Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model. Prostaglandins, leukotrienes, and essential fatty acids. 2009 May; 80(5-6):263-7. doi: 10.1016/j.plefa.2009.03.002. [PMID: 19464862]
  • Kyung Min Kim, Hyun Woo Kim, Jang Han Lee, Jai Won Chang, Jung Sik Park, Soon Bae Kim. Effects of beraprost sodium, an oral prostaglandin i2 analog, on hemostatic factors and inflammation in chronic peritoneal dialysis patients. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 2009 Mar; 29(2):178-81. doi: . [PMID: 19293355]
  • Maho Watanabe, Hitoshi Nakashima, Shizue Mochizuki, Yasuhiro Abe, Atsunori Ishimura, Kenji Ito, Takao Fukushima, Katsuhisa Miyake, Satoru Ogahara, Takao Saito. Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodium. American journal of nephrology. 2009; 30(1):1-11. doi: 10.1159/000195722. [PMID: 19158439]
  • Kazuki Ueda, Takashi Ueyama, Ken-ichi Yoshida, Hiroko Kimura, Takao Ito, Yasuhito Shimizu, Masashi Oka, Yoshihiro Tsuruo, Masao Ichinose. Adaptive HNE-Nrf2-HO-1 pathway against oxidative stress is associated with acute gastric mucosal lesions. American journal of physiology. Gastrointestinal and liver physiology. 2008 Sep; 295(3):G460-9. doi: 10.1152/ajpgi.00204.2007. [PMID: 18617559]
  • Takahisa Yano. [Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2008 Jul; 128(7):1023-9. doi: 10.1248/yakushi.128.1023. [PMID: 18591870]
  • J Lee, H Kim, J C Jeong, E S Park, K W Hwang, S J Yang, J H Jeong. Determination of beraprost in human plasma by a high-performance liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Nov; 859(2):229-33. doi: 10.1016/j.jchromb.2007.09.034. [PMID: 17951119]
  • Maiko Kadowaki, Shiro Mizuno, Yoshiki Demura, Shingo Ameshima, Isamu Miyamori, Takeshi Ishizaki. Effect of hypoxia and Beraprost sodium on human pulmonary arterial smooth muscle cell proliferation: the role of p27kip1. Respiratory research. 2007 Nov; 8(?):77. doi: 10.1186/1465-9921-8-77. [PMID: 17974037]
  • Shunsuke Tawara, Yoshihiro Fukumoto, Hiroaki Shimokawa. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. Journal of cardiovascular pharmacology. 2007 Aug; 50(2):195-200. doi: 10.1097/fjc.0b013e31806befe6. [PMID: 17703136]
  • Anna A Birukova, Tatiana Zagranichnaya, Panfeng Fu, Elena Alekseeva, Weiguo Chen, Jeffrey R Jacobson, Konstantin G Birukov. Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Experimental cell research. 2007 Jul; 313(11):2504-20. doi: 10.1016/j.yexcr.2007.03.036. [PMID: 17493609]
  • Huang-Wei Shen, Yu-Lin Chen, Ching-Yuh Chern, Wai-Ming Kan. The effect of prostacyclin agonists on the differentiation of phorbol ester treated human erythroleukemia cells. Prostaglandins & other lipid mediators. 2007 May; 83(3):231-6. doi: 10.1016/j.prostaglandins.2007.01.012. [PMID: 17481561]
  • Dermot S O'Callaghan, Dermot O'Callaghan, Sean P Gaine. Combination therapy and new types of agents for pulmonary arterial hypertension. Clinics in chest medicine. 2007 Mar; 28(1):169-85, ix. doi: 10.1016/j.ccm.2006.11.011. [PMID: 17338934]
  • Yoshinori Miyahara, Shunsuke Ohnishi, Hiroaki Obata, Kozo Ishino, Shunji Sano, Hidezo Mori, Kenji Kangawa, Soichiro Kitamura, Noritoshi Nagaya. Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats. Biochemical and biophysical research communications. 2006 Nov; 349(4):1242-9. doi: 10.1016/j.bbrc.2006.08.178. [PMID: 16978584]
  • Kazuto Mishima, Anri Baba, Misaki Matsuo, Yoshinori Itoh, Ryozo Oishi. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free radical biology & medicine. 2006 May; 40(9):1564-77. doi: 10.1016/j.freeradbiomed.2005.12.025. [PMID: 16632117]
  • Satoshi Ohta, Makoto Nakamuta, Marie Fukushima, Motoyuki Kohjima, Kazuhiro Kotoh, Munechika Enjoji, Hajime Nawata. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates concanavalin A-induced liver injury in mice. Liver international : official journal of the International Association for the Study of the Liver. 2005 Oct; 25(5):1061-8. doi: 10.1111/j.1478-3231.2005.01143.x. [PMID: 16162167]
  • Takahisa Yano, Yoshinori Itoh, Toshio Kubota, Toshiaki Sendo, Tatsuya Koyama, Takuya Fujita, Kumiko Saeki, Akira Yuo, Ryozo Oishi. A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. The American journal of pathology. 2005 May; 166(5):1333-42. doi: 10.1016/s0002-9440(10)62352-8. [PMID: 15855635]
  • Yoshinori Itoh, Takahisa Yano, Toshiaki Sendo, Ryozo Oishi. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. Journal of pharmacological sciences. 2005 Apr; 97(4):473-88. doi: 10.1254/jphs.crj05002x. [PMID: 15821342]
  • Michio Otsuki, Kayoko Goya, Soji Kasayama. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. Vascular health and risk management. 2005; 1(3):209-15. doi: . [PMID: 17319106]
  • K Fujiwara, A Nagasaka, M Nagata, K Yamamoto, S Imamura, N Oda, Y Sawai, N Hayakawa, A Suzuki, M Itoh. A stable prostacyclin analogue reduces high serum TNF-alpha levels in diabetic patients. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2004 Jul; 112(7):390-4. doi: 10.1055/s-2004-821024. [PMID: 15239025]
  • Takahisa Yano, Yoshinori Itoh, Toshio Kubota, Toshiaki Sendo, Ryozo Oishi. A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. Kidney international. 2004 May; 65(5):1654-63. doi: 10.1111/j.1523-1755.2004.00575.x. [PMID: 15086904]
  • Hirofumi Tomiyama, Tomio Arai, Ken-ichi Hirose, Yutaka Koji, Kohki Motobe, Minoru Yambe, Akira Yamashina. [Effects of acute administration of beraprost sodium on parameters related to atherosclerotic vascular damage in coronary artery disease]. Journal of cardiology. 2004 Feb; 43(2):53-8. doi: NULL. [PMID: 15017784]
  • Takefumi Itoh, Noritoshi Nagaya, Takafumi Fujii, Takashi Iwase, Norifumi Nakanishi, Kaoru Hamada, Kenji Kangawa, Hiroshi Kimura. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. American journal of respiratory and critical care medicine. 2004 Jan; 169(1):34-8. doi: 10.1164/rccm.200303-346oc. [PMID: 14525801]
  • Michael Dandel, Roland Hetzer. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension. Current vascular pharmacology. 2003 Jun; 1(2):171-81. doi: 10.2174/1570161033476754. [PMID: 15320842]
  • Shinichiro Tanaka, Takaaki Akaike, Jun Wu, Jun Fang, Tomohiro Sawa, Michio Ogawa, Toru Beppu, Hiroshi Maeda. Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium. Journal of drug targeting. 2003 Jan; 11(1):45-52. doi: 10.1080/1061186031000086072. [PMID: 12852440]
  • Tetsuji Yamashita, Kenichi Shikata, Mitsuhiro Matsuda, Shinichi Okada, Daisuke Ogawa, Hikaru Sugimoto, Jun Wada, Hirofumi Makino. Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats. Diabetes research and clinical practice. 2002 Sep; 57(3):149-61. doi: 10.1016/s0168-8227(02)00054-2. [PMID: 12126764]
  • Masateru Yamada, Rie Sasaki, Nahoko Sato, Motohiro Suzuki, Mitsutaka Tamura, Teruo Matsushita, Hajimu Kurumatani. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. European journal of pharmacology. 2002 Aug; 449(1-2):167-76. doi: 10.1016/s0014-2999(02)01988-x. [PMID: 12163121]
  • Kaneo Satoh, Yutaka Yatomi, Fumio Kubota, Yukio Ozaki. Small aggregates of platelets can be detected sensitively by a flow cytometer equipped with an imaging device: mechanisms of epinephrine-induced aggregation and antiplatelet effects of beraprost. Cytometry. 2002 Aug; 48(4):194-201. doi: 10.1002/cyto.10128. [PMID: 12210143]
  • Lucie H Clapp, Paul Finney, Sally Turcato, Sandy Tran, Lewis J Rubin, Andrew Tinker. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. American journal of respiratory cell and molecular biology. 2002 Feb; 26(2):194-201. doi: 10.1165/ajrcmb.26.2.4695. [PMID: 11804870]
  • T Nakayama, T Ishikita, H Matsuura, T Saji. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension]. Journal of cardiology. 2001 Nov; 38(5):263-71. doi: NULL. [PMID: 11729726]
  • T Fujita, Y Fuke, A Satomura, M Hidaka, I Ohsawa, M Endo, K Komatsu, H Ohi. PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency. Prostaglandins, leukotrienes, and essential fatty acids. 2001 Oct; 65(4):223-7. doi: 10.1054/plef.2001.0315. [PMID: 11728176]
  • M Ohmori, Y Kitoh, A Kawaguchi, K Harada, K Sugimoto, A Fujimura. Enhanced neutrophil superoxide anion production and its modification by beraprost sodium in spontaneously hypertensive rats. American journal of hypertension. 2001 Jul; 14(7 Pt 1):722-8. doi: 10.1016/s0895-7061(01)01309-7. [PMID: 11465660]
  • Y Aso, K Tayama, K Takanashi, T Inukai, Y Takemura. Changes in skin blood flow in type 2 diabetes induced by prostacyclin: association with ankle brachial index and plasma thrombomodulin levels. Metabolism: clinical and experimental. 2001 May; 50(5):568-72. doi: 10.1053/meta.2001.22517. [PMID: 11319719]
  • T Hayakawa, A Shouzu, M Nishikawa, Y Miyake, H Shimizu, S Omoto, M Inada. Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients. Arzneimittel-Forschung. 2000 Jun; 50(6):535-8. doi: 10.1055/s-0031-1300244. [PMID: 10918946]
  • T Yagi, M Oishi, H Sadamori, T Matsuno, N Tanaka. Successfully treated renal artery stenosis using an oral PGI(2) derivative, beraprost, in cadaveric kidney transplantation. Nephron. 2000 Jun; 85(2):188-9. doi: 10.1159/000045658. [PMID: 10867531]
  • X W Jiang, K Kambara, N Gotoh, K Nishigaki, H Fujiwara. Effects of low-dose Beraprost sodium, a stable prostaglandin I2 analogue, on reperfusion injury to rabbit lungs. American journal of respiratory and critical care medicine. 1998 Nov; 158(5 Pt 1):1669-75. doi: 10.1164/ajrccm.158.5.9609082. [PMID: 9817723]
  • T Yagi, M Oishi, H Matsuda, T Ishikawa, Y Okada, A Endo, N Ishido, K Fujisawa, T Matsuno, N Tanaka. Improvement of myointimal hyperplasia in a patient with transplant renal artery stenosis by oral PGI2. Transplantation proceedings. 1998 Nov; 30(7):3043-4. doi: 10.1016/s0041-1345(98)00922-1. [PMID: 9838341]
  • M Kushiro, K Shikata, H Sugimoto, Y Shikata, N Miyatake, J Wada, M Miyasaka, H Makino. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney international. 1998 May; 53(5):1314-20. doi: 10.1046/j.1523-1755.1998.00881.x. [PMID: 9573547]
  • F Ichida, K Uese, Y Hamamichi, I Hashimoto, S Tsubata, K Fukahara, A Murakami, T Miyawaki. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension. Acta paediatrica Japonica : Overseas edition. 1998 Feb; 40(1):14-9. doi: 10.1111/j.1442-200x.1998.tb01395.x. [PMID: 9583194]
  • M Togawa, M Haneda, S Araki, T Sugimoto, M Isono, H Hidaka, H Yasuda, A Kashiwagi, R Kikkawa. Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cells. European journal of pharmacology. 1997 Oct; 336(2-3):291-4. doi: 10.1016/s0014-2999(97)01208-9. [PMID: 9384245]
  • C T Stier, P N Chander, A Belmonte, R S Inamdar, M Mistry. Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats. Journal of cardiovascular pharmacology. 1997 Sep; 30(3):285-93. doi: 10.1097/00005344-199709000-00003. [PMID: 9300310]
  • Y Kurisu, K Orihashi, T Sueda, H Kajihara, Y Matsuura. Protective effect of beraprost sodium, a stable prostacyclin analogue, on cardiac allograft vasculopathy in rats. Hiroshima journal of medical sciences. 1997 Mar; 46(1):11-9. doi: NULL. [PMID: 9114563]
  • Y Miyaoka, Y Urano, Y Nameda, T Shigekiyo, T Horie, N Sano, S Arase. A case of dermatomyositis complicated by thrombotic thrombocytopenic purpura. Dermatology (Basel, Switzerland). 1997; 194(1):68-71. doi: 10.1159/000246062. [PMID: 9031797]
  • T Kaneko, Y Nagamachi, S Matsuzaki. Suppression of histidine decarboxylase activity in rat oxyntic mucosa by beraprost sodium, a prostacyclin analogue. Prostaglandins. 1997 Jan; 53(1):37-47. doi: 10.1016/s0090-6980(96)00139-6. [PMID: 9068065]
  • M Haneda, S Araki, T Sugimoto, M Togawa, D Koya, R Kikkawa. Differential inhibition of mesangial MAP kinase cascade by cyclic nucleotides. Kidney international. 1996 Aug; 50(2):384-91. doi: 10.1038/ki.1996.327. [PMID: 8840264]
  • M Hiida, O Ushiyama, N Suzuki, A Ohta, K Nagasawa, M Yamaguchi. [The effect of beraprost sodium on the Raynaud's phenomenon]. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology. 1996 Jun; 19(3):193-200. doi: 10.2177/jsci.19.193. [PMID: 8810544]
  • T Saji, Y Ozawa, T Nakayama, H Matsuura, R Hashiguchi, N Matsuo, H Muto, J Yamazaki, T Morishita, T Saito. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension]. Journal of cardiology. 1996 Apr; 27(4):197-205. doi: NULL. [PMID: 8642506]
  • E Kakishita, T Nakajima, A Suehiro, T Koyama, M Ueda, H Tsujioka, H Yoshimoto. Studies of the pathogenesis and management of thrombotic thrombocytopenic purpura. Polish journal of pharmacology. 1996 Mar; 48(2):179-84. doi: NULL. [PMID: 9112648]
  • M Shindo, M Majima, T Ohno, K Sugimoto, T Ohwada. Induction mechanism of small intestinal lesions caused by intravenous injection of endotoxin in rats. Surgery today. 1996; 26(8):610-7. doi: 10.1007/bf00311666. [PMID: 8855494]
  • L N Wang, Z Tang, I Shou, M Fukui, Y Tomino. Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nephron. 1996; 73(4):637-43. doi: 10.1159/000189152. [PMID: 8856263]
  • M Nishimura, O Nozaki, H Nakano, H Tsuchida, K Yamada. The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM. Journal of diabetes and its complications. 1995 Oct; 9(4):330-3. doi: 10.1016/1056-8727(95)80034-c. [PMID: 8573759]
  • Y Ueno, H Koike, S Nishio. Beneficial effects of beraprost sodium, a stable prostacyclin analogue, in diabetic cardiomyopathy. Journal of cardiovascular pharmacology. 1995 Oct; 26(4):603-7. doi: 10.1097/00005344-199510000-00015. [PMID: 8569222]
  • Y Yajima, T Moriya, K Matoba, A Kanamori. Ultrastructural study of glomerular basement membrane in diabetic rats by the quick-freezing and deep-etching method. Journal of diabetes and its complications. 1995 Oct; 9(4):288-91. doi: 10.1016/1056-8727(95)80024-9. [PMID: 8573749]
  • F Umeda, T Kuroki, H Nawata. Prostaglandins and diabetic nephropathy. Journal of diabetes and its complications. 1995 Oct; 9(4):334-6. doi: 10.1016/1056-8727(95)80035-d. [PMID: 8573760]
  • K Sakata, T Hoshino, H Yoshida, T Kaburagi, A Takada. Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina. Cardiovascular drugs and therapy. 1995 Aug; 9(4):601-7. doi: 10.1007/bf00878093. [PMID: 8547211]